Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-01-11
2005-01-11
Myers, Carla J. (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C536S023500, C536S024310, C536S024330
Reexamination Certificate
active
06841350
ABSTRACT:
A method of diagnosing prostate cancer in a human patient comprising the steps of obtaining a sample containing nucleic acid and/or protein from prostate cells of a patient, and determining whether the sample contains a level of Pax 2 nucleic acid or protein associated with prostate cancer. A method of treating prostate cancer comprising the step of administering to the patient an agent which selectively prevents the function of Pax 2. A genetic construct comprising a nucleic acid encoding a molecule capable of preventing the function of Pax 2 expressed in a prostate cell.
REFERENCES:
patent: 4376110 (1983-03-01), David et al.
patent: 4486530 (1984-12-01), David et al.
patent: 5747250 (1998-05-01), Gruss et al.
patent: 6071697 (2000-06-01), Sosa-Pineida et al.
patent: WO 94 03196 (1994-02-01), None
patent: 0 655 926 (1995-06-01), None
patent: WO 9403196 (1994-02-01), None
patent: WO 9532214 (1995-11-01), None
patent: WO 9602674 (1996-02-01), None
patent: WO 9715686 (1997-05-01), None
Gray et al. Cancer Research 55, 4800-4803, Nov. 1, 1995.*
Adams, et at., “Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testes,”Genes&Development6:1589-1607 (1992).
Balaguer, et at., “Quantification of DNA sequences obtained by polymerase chain reaction using a bioluminescent adsorbent,”Analytical Biochemistry195:105-110 (1991).
Bernasconi, et al., “Induction of apoptosis in rhabdomyosarcoma cells through down-regualtion of PAX proteins,”Proc Natl Acad Sci USA93:13164-69 (1996).
Bischoff, et al., “An adventure mutant that replicates selectively in p53-deficient human tumor cells,”Science274:373-376 (1996).
Brawer, “Prostate Specific Antigen,”Acta Oncol.30:161-168 (1991).
Brothman, et al., “Frequency and pattern of karyotypic abnormalities in human prostate cancer,”Cancer Research50:3795-3803 (1990).
Busslinger, at al., “The role of BSAP (Pax-5) in B-cell development.”Current Opinion in Genetics and Development5:595-601 (1995).
Cancer Statistics: RegistrationsEngalnd and Wales OPCS MWI No. 22, Her Majesty's Stationery Office (1994).
Cannon-Albright & Eeles, “Progress in prostate cancer,”Nature Genetics9:336-338 (1995).
Chamberlain, et al., “Report prepared for the health technology assessment panel of the NHS execution on the diagnosis, management, treatment and costs of prostate cancer an England and Wales,”British Journal of Urology79(Suppl.3):1-32 (1997).
Chan, et al., “Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study,”Science279:563-566 (1998).
Compton, Nucleic acid sequence-based amplification,Nature350:91-92 (1991).
Cotten, et al., “High-efficiency receptor-mediated delivery of small and large (48 kilobase) gene constructs using the endosome-disruption activity of detective or chemically inactivated adenovirus particles,”Proc Natl Acad Sci USA89:6094-6098 (1992).
Culver, et al.. “In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors,”Science256:1550-1552 (1992).
Curiel, “Adenovirus facilitation of molecular conjugate-mediated gene transfer,” Prog Med Virol 40:1-18 (1993).
Dicesare, et al., “A high-sensitivity electrochemiluminescence-based detection system for automated PCR product quantitation,”BioTechniques15:152-157 (1993).
Dressler, et al., “Deregulation ofPax-2 expression in transgenic mice generates severe kidney abnormalities,”Nature362:665-67 (1993).
Dressler, et at., “Pax2, a new murine paired-box-containing gene and its expression in the developing excretory system,”Development109(4): 787-795 (1990).
Future Oncology“Prostate Cancer-Part II: Diagnosis, Staging, Prognosis, Screening, and Novel Molecular Markers,” 3(12): 1998.
Gann, et al., “A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer,”JAMA273: 289-294 (1995).
Gao, et al., “Diagnostic and prognostic markers for human prostate cancer,”The Prostate31:264-281 (1997).
Gao, et al., “High frequency of mutator phenotype in human prostatic adenocarcinoma,”Oncogene9:2999-3003 (1994).
Gleason, “Classification of prostatic carcinomas,”Cancer Chemother Rep.50:125-128 (1966).
Gnarra & Dressler, “Expression of Pax-2 in human renal cell carninoma and growth inhibition by antisense oligonucleotides,”Cancer Research55(18):4092-8 (1995).
Jacobs, at al., “Tharmal stability of oligonucleotide duplexes is sequence independent in tetraalkylammonium application to identifying recombinant DNA clones,”Nucl. Acids Res.16:4367 (1988).
Khoubehi, et al., “The expression of the PAX2 in human prostate cancer,”Am J Human Genetics65(Suppl. 4):A132 (1999).
Khoubehi, et al., “Expression of the developmental and oncogenic PAX2 gene in human prostate cancer,”J Urology165(6.1): 2115-2120.
Koontz, et al., “Mitomycin, for patients who have failed on thiotepa,”Urology26(4 Suppl.):30-31 (1985).
Kuriyama, et al., “A Potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector,”Cell Structure and Function16:503-510 (1991).
Ledley, “Nonviral gene therapy: The promise of genes as pharmaceutical products,”Human Gene Therapy6:1129-1144 (1995).
Li, et al., “PTEN, a putative Protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer,”Science275:1943-1947 (1997).
Lundwall, “Characterization of the gene for prostate-specific antigen, a human glandular kallikrein,”Biochem. Biophys. Res. Comm.161(3): 1151-1159 (1989).
Martin & Papahadjopoulos, et al., “Irreversible coupling of immunoglobulin fragments to preformed vesicles,”J Biol Chem257:286-88 (1982).
Massenkeil, et al., “P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, I7p, and 18q are confined to advanced prostate cancer,”Anticancer Res.14(6B): 2785-2790 (1994).
Maulbecker & Gruss, “The oncogenic potential of Pax genes,”EMBO JournaI12(6): 2361-2367 (1993).
Michael, et al., “Addition of a short peptide ligand to the adenovirus fiber protein,”Gene Therapy2:660-668 (1982).
Miller & Vile, “Targeted vectors for gene therapy,”FASEB Journal9(2): 190-199 (1995).
Mortality Statistics: Cause.England and Wales. OPCS DH2 19, Her Majesty's Stationary Office, 1993.
Nassander, et at., “In vivo targeting of OV-TL 3 immunoliposomes to Ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice,”Cancer Research52:646-653 (1992).
Nihel, et al., “Localization of metastasis suppressor gene(s) for rat prostatic cancer to the long arm of human chromosome 10,”Genes, Chromosomes&Cancer14(2): 112-119 (1995).
Phelps & Dressler, “Aberrant expression of Pax-2 in Danforth's short tail (Sd) mice,”Developmental Biology157(1): 251-258 (1993).
Pogrebniak, et al., “Targetted phototherapy with sensitizer-monoclonal antibody conjugate and light,”Surgical Oncology2(1): 31-42, 1993.
Riegman, et al., “Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene,”Biochem Biophys. Res. Comm.159(1): 95-102 (1989).
Ryan, et al., “Repression at Pax-2 by WT1 during normal kidney development,”Development121: 867-875 (1995).
Saiki, et al., “Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase,”Science239:487-491 (1988).
Sanyanusin, et al., “Fenomic structure of the human PAX2 gene,”Genomics35(1): 258-261 (1996).
Schäfer, et al., “Molecular cloning and characterization of a human PAX-7 cDNA expressed in normal and neoplastic myocytes,”Nuc. Acids Res.22(22): 4574-4582 (1994).
Smith & Ca
Adshead James
Kessling Anna Maria
Khoubehi Bijan
Ogden Christopher William
Pabst Patent Group LLP
Sakelaris Sally A
The North West London Hospitals NHS Trust of Northwick Park Hosp
LandOfFree
Methods of diagnosing prostate cancer through the detection... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of diagnosing prostate cancer through the detection..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of diagnosing prostate cancer through the detection... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3437625